Features of changes in insulin-like growth factor-1 in patients with chemoresistant pulmonary tuberculosis who are on palliative treatment

Authors

  • H. V. Khudiakov Zaporizhzhia State Medical University, Ukraine,

DOI:

https://doi.org/10.14739/2409-2932.2019.1.159134

Keywords:

drug-resistant pulmonary tuberculosis, palliative care, insulin-like growth factor-1

Abstract

 

One of the causes of death of patients with pulmonary tuberculosis is cachexia. In the available literature, there are no data on the study of changes in the significate of insulin-like growth factor-1 (IGF-1) in patients with chemo-resistant pulmonary tuberculosis (CRTB) with a body mass deficit.

The purpose of the work is to determine the level of IGF-1 in the serum of patients with CRHT of the lungs who are under palliative treatment, and to establish the features of its change depending on the body mass index (BMI).

Materials and methods. The main group of follow-up consisted of 52 patients with CRTB of lungs, who are on palliative treatment (mean age 39.4 ± 1.8 years). The comparison group included 29 patients who receive anti-mycobacterial therapy for category 4 in accordance with the profile of drug resistance, the average age was 41.3 ± 1.8 years. The difference in P < 0.05 was considered statistically significant. The study of the level of IGF-1 in serum was performed by the method of solid-phase enzyme immunoassay on an Sirio S immunoassay reader using the Human IGF-1 ELISA kit (Germany), (ng/ml).

Results. In the main group of patients, the level of IGF-1 in serum was 5.09 (4.08; 7.81) ng/ml, which is 1.4 times lower (P < 0.01) than in the comparison group. In palliative CRTB patients with a BMI of ≤18.1 kg/m2, the serum IGF-1 level was 4.04 (2.38; 4.51) ng/ml, which was significantly lower by 1.9 times (P < 0.05) than in palliative patients with a BMI > 18.1 kg/m2 and 1.7 times than in the comparison group. It was established that, in patients with CRTB, who got the palliative care, a decrease in the level of IGF-1 in serum was significantly directly dependent on a decrease in BMI: in main group 1 (r = 0.91; P = 0.001) and in main group 2 (r = 0.97; P = 0.001).

Conclusions. In patients with CRTB of the lungs who got palliative treatment, a significant decrease in the serum IGF-1 level of 1.4 times is determined compared to patients with CRTB of the lungs who receive antimycobacterial therapy. At the same time, in patients CRTB of the lungs, who got palliative care and had a body mass index of ≤18.1 kg/m2, the level of serum IGF-1 is significantly lower by 1.9 times compared with patients with a body mass index of >18.1 kg/m2. In patients CRTB, who got palliative care, a decrease in serum IGF-1 levels reliably depends on a decrease in body mass index. Significate of serum IGF-1 can be used as an early marker of the increase and progression of cachexia.

 

References

Kravchun, P. G., Lapshina, L. A., Zolotajkina, V. I.  Borzova E. Yu. (2015). Poterja massy tela i kakheksiya [Loss of body weight and cachexia]. Novosti mediciny i farmacii, 6(535), 22–27 [in Russian].

Raznatovskaya, E. N. (2013). Analiz prichin smerti bol'nykh khimiorezistentnym tuberkulezom legkih [Analysis of causes of death in patients with resistant pulmonary tuberculosis]. Klinicheskaya infektologiya i parazitologiya, 2(05), 29–39. [in Russian].

Harmatina, O. Yu. (2015). Insulinopodobnyj faktor rosta-1: nejrofiziologicheskie aspekty [Insulin like growth factor-1: neurophysiological aspects]. Medychna hidrologiia ta reabilitatsiia, 13(1–3), 67–71. [in Russian].

Gennadinik, A. G.  Nellaeva, A. A. (2010). Rol' insulinopodobnogo faktora rosta-1 v metabolizme, regulyacii i kletochnogo obnovleniya v processakh stareniya [The role of insulin-like growth factor-1 in metabolism, regulation and cellular renewal in the aging process]. Ozhirenie i metabolizm, 2, 10–15. [in Russian].

Ukraina. MOZ. (2014). Unifikovanyi klinichnyi protokol pervynnoi, vtorynnoi (spetsializovanoi) ta tretynnoi (vysokospetsializovanoi) medychnoi dopomohy doroslym. Tuberkuloz: nakaz MOZ Ukrainy vid 31.12.2014 r. №620 [Unified clinical protocols of primary, secondary (specialized) and tertiary (highly specialized) medical care for adults «Tuberculosis». Order of the Ministry of Health of Ukraine from September 04, 2014 №620]. [in Ukrainian].

Downloads

How to Cite

1.
Khudiakov HV. Features of changes in insulin-like growth factor-1 in patients with chemoresistant pulmonary tuberculosis who are on palliative treatment. Current issues in pharmacy and medicine: science and practice [Internet]. 2019Mar.11 [cited 2024Nov.13];(1). Available from: http://pharmed.zsmu.edu.ua/article/view/159134

Issue

No. 1 (2019)

Section

Original research

License

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.     Лицензия Creative Commons
    2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
    3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)